Serotonin syndrome

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Serotonin excess can follow therapeutic prescribing when mechanisms are combined, not only deliberate overdose. Monoamine-oxidase inhibition creates particularly severe interactions, including with serotonergic antidepressants, some opioids and linezolid. Pharmacy records may omit over-the-counter cough preparations, St John's wort, recreational substances and recent medicines from another prescriber. Exact ingestion time, formulation, dose, metabolism and renal or hepatic impairment shape duration.

The examination separates serotonin syndrome from other hyperthermic states. Clonus, brisk reflexes and tremor favour serotonin toxicity. Neuroleptic malignant syndrome evolves more slowly with generalised lead-pipe rigidity and hyporeflexia after dopamine blockade. Anticholinergic poisoning causes dry skin and reduced bowel activity rather than sweating and diarrhoea. Sepsis, meningitis, sympathomimetic toxicity, heatstroke, thyrotoxicosis and malignant hyperthermia require parallel consideration. Severe rigidity may eventually obscure clonus, so early findings and drug history matter.

Most mild cases improve within a day after short-acting medicines are stopped and supportive care is given, but long-acting or irreversible inhibitors prolong toxicity. Benzodiazepines treat agitation, seizures and motor drive without adding serotonergic or antipsychotic burden. For extreme hyperthermia, rapid sedation, intubation, non-depolarising neuromuscular paralysis and aggressive external cooling prevent protein denaturation and organ failure. Toxicology advice should govern cyproheptadine and cardiovascular management because evidence is limited and some agents worsen hypotension or temperature. Blood-pressure treatment must be short acting and physiology led because autonomic changes can reverse quickly as neuromuscular toxicity settles.

Key points

Serotonin syndrome is a predictable toxicity from excessive serotonergic activity, most often after combination, overdose, dose escalation or a pharmacokinetic interaction rather than an idiosyncratic allergy.
Symptoms usually begin within hours of a new exposure and combine mental-state change, autonomic activation and neuromuscular hyperactivity.
Spontaneous, inducible or ocular clonus is the most discriminating bedside sign; hyperreflexia and tremor are often more prominent in the legs.
Agitation, diaphoresis, mydriasis, tachycardia, hypertension, diarrhoea and increased bowel sounds accompany the motor findings, while severe cases become hyperthermic and acidotic.
Common contributors include SSRIs or SNRIs with MAO inhibitors, tramadol, linezolid, lithium, dextromethorphan, MDMA, certain opioids and interacting herbal or illicit products.
A careful timeline must include medicines recently stopped because long half-lives, especially fluoxetine, maintain interaction risk after cessation.
Hunter criteria use exposure plus clonus, agitation, diaphoresis, tremor, hyperreflexia, hypertonia and temperature, but diagnosis remains clinical and mimics still require assessment.
Stop serotonergic medicines, reduce stimulation, give intravenous fluids as appropriate, titrate benzodiazepines and use active external cooling; avoid physical struggle.
Severe temperature is produced by muscle activity rather than a hypothalamic fever set point, so paralysis and ventilation may be life saving whereas antipyretics are ineffective.
Cyproheptadine is an oral or enteral serotonin antagonist sometimes used for persistent moderate or severe toxicity under toxicology advice; supportive care remains the foundation.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Combined serotonergic medicines

SSRIs or SNRIs combined with MAO inhibition, tramadol, linezolid, lithium or other serotonergic agents can create excessive signalling.

Overdose or dose escalation

Intentional overdose, rapid increase or reduced clearance can raise serotonergic exposure even without a second medicine.

Pharmacokinetic interaction

Enzyme inhibition and long drug half-lives can preserve hazardous concentrations after a medicine appears to have been stopped.

Illicit and non-prescription exposure

MDMA, dextromethorphan, certain opioids and herbal products may be overlooked unless the exposure history is non-judgemental and complete.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Synaptic serotonin excess
Excess production, release, receptor stimulation or impaired breakdown raises serotonergic activity across central and peripheral nervous systems.
2
Neuromuscular hyperactivity
Spinal and brainstem receptor overactivation produces tremor, hyperreflexia and spontaneous, inducible or ocular clonus on examination.
3
Autonomic and mental-state activation
Central and peripheral signalling causes agitation, diaphoresis, mydriasis, tachycardia, pressure change and increased gastrointestinal activity during toxicity.
4
Muscle-generated hyperthermia
Severe sustained contraction produces heat, acidosis and rhabdomyolysis that can progress to multi-organ failure without rapid control.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Rapid exposure link

Agitation and tremor begin within hours of adding, increasing or overdosing a serotonergic medicine or combining it with an MAO inhibitor.

Inducible clonus

Repeated rhythmic ankle movement after sudden dorsiflexion, especially with agitation or diaphoresis, is a high-value sign of serotonin toxicity.

Ocular clonus

Spontaneous or induced rapid eye oscillation with agitation and sweating supports the diagnosis when limb examination is difficult.

Autonomic and gut activation

Mydriasis, sweating, tachycardia, blood-pressure elevation, hyperactive bowel sounds, vomiting or diarrhoea accompany hyperreflexia.

Severe hypermetabolismRed flag

Temperature above 40 degrees, sustained rigidity, seizure, acidosis or rapidly rising CK indicates life-threatening toxicity requiring intubation and paralysis.

NMS contrast

A several-day onset after dopamine blockade with diffuse rigidity and reduced reflexes favours neuroleptic malignant syndrome rather than early clonus-dominant serotonin toxicity.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Complete exposure timelineFirst step
Why
Identify serotonergic combinations, overdose, long half-life and metabolic interaction.
Interpretation and limitations
Include prescriptions, recent discontinuations, antibiotics, analgesics, cough medicines, supplements and illicit drugs; no serum serotonin level diagnoses the syndrome.
02
Core temperature and repeated neuromuscular examination
Why
Grade severity and document clonus, reflexes and evolving rigidity.
Interpretation and limitations
Use a reliable core method in severe illness; loss of visible clonus during extreme rigidity does not necessarily represent improvement.
03
Creatine kinase, renal profile and electrolytes
Why
Detect rhabdomyolysis, kidney injury and dangerous potassium change.
Interpretation and limitations
Trend with urine output and urinalysis; CK does not establish the diagnosis but guides complication management.
04
Blood gas, lactate and glucose
Why
Identify acidosis, hypermetabolism, seizure consequence and physiological deterioration.
Interpretation and limitations
Worsening acidosis or lactate with uncontrolled rigidity supports urgent sedation, paralysis and organ support rather than additional diagnostic delay.
05
ECG and cardiac monitoring
Why
Detect dysrhythmia, QT effects and co-ingested cardiotoxic medicines.
Interpretation and limitations
QRS or QT abnormalities may point to additional overdose mechanisms and change bicarbonate or electrolyte treatment.
06
Infection and neurological investigations
Why
Exclude sepsis, meningitis, encephalitis or seizure when history and examination are not definitive.
Interpretation and limitations
Cultures, imaging, lumbar puncture and EEG are selected by stability and phenotype; a serotonergic exposure can coexist with infection.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Neuroleptic malignant syndrome

Slower evolution with profound rigidity and reduced reflexes after dopamine disruption favours NMS over clonus-predominant serotonin toxicity.

Anticholinergic or sympathomimetic toxicity

Dry skin and reduced bowel sounds support anticholinergic poisoning, while stimulant toxicity lacks the characteristic clonus pattern.

Malignant catatonia

A preceding psychomotor syndrome with mutism, negativism or posturing supports catatonia, although autonomic and motor overlap can be substantial.

Sepsis or CNS infection

Fever, confusion and shock require infection investigation; a medicine history and clonus should not suppress cultures or antimicrobial treatment when indicated.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01RecognitionUse clonus and the medicine timelineFirst stepAgitation, sweating and abnormal movements follow a medicine change or overdose.

1Stop all serotonergic and non-essential psychoactive medicines, secure an accurate exposure history and contact the National Poisons Information Service.
2Examine pupils, skin, bowel sounds, reflexes and spontaneous, ocular and inducible clonus while measuring core temperature and cardiorespiratory stability.
3Consider Hunter criteria but investigate infection, NMS, anticholinergic or sympathomimetic toxicity and malignant hyperthermia where discordant findings remain.

02Mild or moderateRemove exposure and settle motor activityThe patient has clonus and autonomic activation without severe hyperthermia or organ failure.

1Move to a low-stimulation monitored area, give intravenous or oral fluids according to hydration and use titrated benzodiazepine for agitation and tremor.
2Apply external cooling for temperature rise and avoid restraint, antipyretic-only treatment and new dopamine antagonists that complicate the differential.
3Observe until neuromuscular and autonomic findings resolve for an interval appropriate to the longest-acting exposure, repeating laboratory tests if severity increases.

03Severe toxicityStop heat generationTemperature, rigidity, seizure, acidosis or consciousness deteriorates despite initial care.

1Call critical care, deeply sedate, secure the airway and use a non-depolarising neuromuscular blocker when muscle activity drives dangerous hyperthermia.
2Continue rapid external cooling, intravenous fluid and treatment of hyperkalaemia, rhabdomyolysis, seizures and coagulation or renal complications.
3Discuss enteral cyproheptadine and haemodynamic strategy with toxicology, recognising uncertain evidence and the absence of an intravenous formulation.

04PreventionReconstruct safer prescribingToxicity has resolved and ongoing pain, mood or infection treatment is needed.

1Identify the causal combination and pharmacokinetic mechanism, document it prominently and report an adverse reaction through the appropriate regulator route when indicated.
2Respect washout periods for MAO inhibitors and long-half-life antidepressants, involving pharmacy before linezolid, tramadol or another interacting medicine is considered.
3Provide patient-held advice on over-the-counter and illicit serotonergic products and arrange mental-health assessment when the exposure was intentional.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Reduces agitation, seizure and muscle activity, thereby lowering heat production.

Lorazepam or diazepam

Titrate intravenous or oral benzodiazepine in small repeated doses using current BNF and toxicology advice, with continuous respiratory observation in severe illness.

Respiratory depression, aspiration, delirium and prolonged sedation can occur, especially with co-ingested depressants; airway readiness must match dose escalation.

Antagonises serotonin receptors in persistent moderate or severe toxicity after exposure withdrawal and supportive care.

Cyproheptadine

Toxicology may recommend an initial enteral dose followed by repeat and maintenance doses from current TOXBASE guidance; it cannot be given intravenously.

Evidence is limited and anticholinergic sedation and hypotension can complicate assessment; never delay airway control, paralysis or cooling to obtain it.

Stops muscle-generated heat in life-threatening hyperthermia when sedation alone is insufficient.

Non-depolarising neuromuscular blocker

Critical-care clinicians choose a weight-based intubation and infusion regimen using local rapid-sequence and temperature-emergency protocols.

Paralysis hides seizures and neurological signs and mandates full ventilation, sedation and monitoring; avoid succinylcholine when hyperkalaemia or rhabdomyolysis increases risk.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Hyperthermia and rhabdomyolysis

Sustained muscle activity causes severe heat, muscle breakdown, hyperkalaemia and kidney injury during severe uncontrolled toxicity.

Seizures and cerebral injury

Extreme serotonergic activation can provoke seizures, delirium, coma and secondary hypoxic brain damage during severe toxicity.

Coagulation and multi-organ failure

Acidosis, hyperthermia and shock can trigger disseminated coagulation, hepatic injury, respiratory failure and death when untreated.

Aspiration and treatment injury

Agitation, reduced consciousness and sedation increase aspiration and airway risk, while physical restraint worsens heat generation.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Repeat core temperature, clonus, reflexes, rigidity, mental state and autonomic observations until a sustained downward trajectory is clear.
Trend CK, potassium, creatinine, bicarbonate, lactate, liver tests, coagulation and urine output in moderate or severe toxicity.
Use continuous ECG and blood-pressure monitoring when hyperthermia, co-ingestion, electrolyte disturbance or cardiovascular treatment is present.
Observe long enough for long-acting, modified-release or irreversible MAO-inhibiting exposures and watch for recurrence after apparent sedation response.
Monitor for aspiration, pressure injury and venous thrombosis during immobility, especially after intubation and paralysis.
Before discharge reconcile all serotonergic medicines and ensure pharmacy, primary care and mental-health teams receive the causal interaction plan.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Clonus carries weight

Inducible ankle clonus with agitation or sweating is more diagnostically useful than non-specific fever, tachycardia or raised creatine kinase.

Onset is usually fast

A syndrome developing within hours of a serotonergic change fits better than NMS, which more often evolves over several days.

Fluoxetine lingers

Its active metabolite creates interaction risk for weeks, making a recently stopped prescription relevant to an MAO-inhibitor exposure.

Antipyretics miss mechanism

The dangerous temperature comes from sustained muscular activity, so sedation, paralysis and external cooling are the effective controls.

No blood test confirms

Serotonin concentration does not diagnose tissue toxicity; bedside neuromuscular findings and exposure history drive recognition.

11Common pitfallsFrequent interpretation and management errors.

01
Missing over-the-counter dextromethorphan or illicit serotonergic exposure.
02
Ignoring a recently stopped long-half-life antidepressant.
03
Calling hyperreflexia and clonus lead-pipe rigidity.
04
Using paracetamol as definitive treatment for extreme hyperthermia.
05
Restraining an agitated patient and increasing muscle heat.
06
Waiting for a serotonin level that has no diagnostic role.
07
Giving cyproheptadine while delaying intubation and paralysis.